金吾财讯 | iking Therapeutics(VKTX)宣布，其试验性药物VK2735在较高剂量下相比早期配方能更有效地减轻患者体重，这为其与诺和诺德(NVO)和礼来(LLY)的重磅药物竞争奠定了坚实基础。在一项早期研究中，服用100毫克VK2735的受试者在28天内平均减重8.2%，相比之下，服用安慰剂的患者减重6.8%。据悉，该公司于周日在圣安东尼奥举行的肥胖周会议上介绍了这一研究成果。投资者对Viking公司打入减肥药市场的潜力表示看好，今年其股价已上涨三倍。据预测，到2020年，减肥药市场规模将达到1300亿美元。Viking的药物以易于服用的药丸形式出现，有望成为目前市场上占主导地位的注射剂的替代品，产生重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.